KBLP-001 is under clinical development by KoBioLabs and currently in Phase II for Plaque Psoriasis (Psoriasis Vulgaris). According to GlobalData, Phase II drugs for Plaque Psoriasis (Psoriasis Vulgaris) have a 47% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how KBLP-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

KBLP-001 overview

KBLP-001 is under development for the treatment of inflammatory bowel disease (ulcerative colitis), atopic dermatitis, plaque psoriasis. It is administered orally. The drug candidate is single strain KBL697 live bacterial drug developed based on the Microbiome metabolic disease control technology.

KoBioLabs overview

KoBioLabs focuses on developing microbiome-based drugs for immune, metabolic and neurological disorders. The company is investigating KBLP-001 project to treat psoriasis; KBLP-007 and KBLP-006 drugs against inflammatory bowel disease (IBD); KBLP-002 program for the treatment of asthma and atopic dermatitis; and KBLP-005 project targeting immune-oncology indications. It is also evaluating KBLP-004 drug for NASH (non-alcoholic steatohepatitis); KBLP-009 program against liver disease; and KBLP-010 project for the treatment autism spectrum disorder. KoBioLabs utilizes Smartiome technology that consists of BaxData, a human microbiome database; BaxBank, a collection of bacterial isolates from the human donor samples; and BaxPlore, an evaluation platform to develop its drugs. KoBioLabs is headquartered in Seongnam-si, Gyeonggi-do, South Korea.

For a complete picture of KBLP-001’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.